{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T02:55:47Z","timestamp":1794970547705,"version":"4.9.1"},"reference-count":155,"publisher":"American Society of Hematology","issue":"12","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6,24]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>T-cell receptor (TCR) therapies are a promising modality for the treatment of cancers, with significant efforts being directed toward acute myeloid leukemia (AML), a particularly challenging disease. Chimeric antigen receptor (CAR) T cells targeting single surface antigens have shown remarkable efficacy for B-cell lymphoblastic leukemia, lymphomas, and multiple myeloma. However, AML presents formidable obstacles to the effectiveness of CAR T cells because of the widespread expression of heterogenous leukemia immunophenotypes and surface antigen targets additionally present on normal myeloid cells. TCR therapies are an evolving field of cell therapies that allow targeting intracellular antigenic peptides presented via HLA molecules. The development of TCR therapy for AML is progressing rapidly through preclinical research and successful clinical trials. This review specifically explores the antigens targeted in AML, the diverse methodologies and strategies used in TCR identification, and preclinical TCR T-cell development. The review also discusses innovative molecular designs to improve functional efficacy, mitigate safety concerns, and overcome HLA restrictions. Specific outcomes of early clinical trials targeting important antigens Wilms tumor gene 1, preferentially expressed antigen in melanoma, and minor histocompatibility antigen HA-1 are also highlighted. Ultimately, this review underscores why TCR therapy is poised to become an indispensable component of AML immunotherapy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024014105","type":"journal-article","created":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T20:58:40Z","timestamp":1736974720000},"page":"3069-3089","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":17,"title":["Current developments in T-cell receptor therapy for acute myeloid leukemia"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3388-1698","authenticated-orcid":false,"given":"Sayali","family":"Gore","sequence":"first","affiliation":[{"name":"1School of Medical Science, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia"},{"name":"2Children\u2019s Cancer Research Unit, The Children\u2019s Hospital at Westmead, Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7849-7139","authenticated-orcid":false,"given":"Emily","family":"Blyth","sequence":"additional","affiliation":[{"name":"1School of Medical Science, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia"},{"name":"3Centre for Cancer Research, Westmead Institute for Medical Research, Sydney, NSW, Australia"},{"name":"4Blood Transplant and Cell Therapies Program, Department of Haematology, Westmead Hospital, Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7018-8702","authenticated-orcid":false,"given":"Marie","family":"Bleakley","sequence":"additional","affiliation":[{"name":"5Translational Science and Therapeutics, Fred Hutchinson Cancer Center, Department of Pediatrics, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9541-3876","authenticated-orcid":false,"given":"Koon","family":"Lee","sequence":"additional","affiliation":[{"name":"3Centre for Cancer Research, Westmead Institute for Medical Research, Sydney, NSW, Australia"},{"name":"4Blood Transplant and Cell Therapies Program, Department of Haematology, Westmead Hospital, Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7519-9489","authenticated-orcid":false,"given":"Kenneth","family":"Micklethwaite","sequence":"additional","affiliation":[{"name":"3Centre for Cancer Research, Westmead Institute for Medical Research, Sydney, NSW, Australia"},{"name":"4Blood Transplant and Cell Therapies Program, Department of Haematology, Westmead Hospital, Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8616-6727","authenticated-orcid":false,"given":"Kavitha","family":"Gowrishankar","sequence":"additional","affiliation":[{"name":"1School of Medical Science, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia"},{"name":"2Children\u2019s Cancer Research Unit, The Children\u2019s Hospital at Westmead, Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,6,16]]},"reference":[{"key":"2025062410165153000_bib1","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.blre.2019.04.005","article-title":"Epidemiology of acute myeloid leukemia: recent progress and enduring challenges","volume":"36","author":"Shallis","year":"2019","journal-title":"Blood Rev"},{"issue":"5","key":"2025062410165153000_bib2","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1002\/pbc.24464","article-title":"Epidemiology of childhood acute myeloid leukemia","volume":"60","author":"Puumala","year":"2013","journal-title":"Pediatr Blood Cancer"},{"issue":"16","key":"2025062410165153000_bib3","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1182\/blood-2012-03-362608","article-title":"Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel","volume":"120","author":"Creutzig","year":"2012","journal-title":"Blood"},{"issue":"2","key":"2025062410165153000_bib4","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41408-021-00425-3","article-title":"Acute myeloid leukemia: current progress and future directions","volume":"11","author":"Kantarjian","year":"2021","journal-title":"Blood Cancer J"},{"key":"2025062410165153000_bib5","first-page":"3","volume-title":"Acute Leukemias. Hematologic Malignancies","author":"Sweet","year":"2021"},{"issue":"4","key":"2025062410165153000_bib6","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"issue":"11","key":"2025062410165153000_bib7","doi-asserted-by":"crossref","first-page":"3511","DOI":"10.1073\/pnas.81.11.3511","article-title":"T-cell-mediated cytotoxicity against autologous malignant melanoma: analysis with interleukin 2-dependent T-cell cultures","volume":"81","author":"Knuth","year":"1984","journal-title":"Proc Natl Acad Sci"},{"issue":"4770","key":"2025062410165153000_bib8","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1126\/science.3489291","article-title":"A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes","volume":"233","author":"Rosenberg","year":"1986","journal-title":"Science"},{"issue":"25","key":"2025062410165153000_bib9","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJM198812223192527","article-title":"Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report","volume":"319","author":"Rosenberg","year":"1988","journal-title":"N Engl J Med"},{"issue":"11","key":"2025062410165153000_bib10","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1038\/s41375-023-02033-5","article-title":"Persistence of ex vivo expanded tumour and pathogen specific T-cells after allogeneic stem cell transplant for myeloid malignancies (the INTACT study)","volume":"37","author":"Jiang","year":"2023","journal-title":"Leukemia"},{"issue":"6","key":"2025062410165153000_bib11","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1038\/s41409-018-0383-2","article-title":"Post-transplant immunotherapy with WT1-specific CTLs for high-risk acute myelogenous leukemia: a prospective clinical phase I\/II trial","volume":"54","author":"Kim","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"174","key":"2025062410165153000_bib12","doi-asserted-by":"crossref","first-page":"174ra27","DOI":"10.1126\/scitranslmed.3004916","article-title":"Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patients","volume":"5","author":"Chapuis","year":"2013","journal-title":"Sci Transl Med"},{"issue":"19","key":"2025062410165153000_bib13","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1182\/blood.2020009471","article-title":"Clinical effects of administering leukemia-specific donor T cells to patients with AML\/MDS after allogeneic transplant","volume":"137","author":"Lulla","year":"2021","journal-title":"Blood"},{"issue":"8","key":"2025062410165153000_bib14","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1182\/bloodadvances.2021006831","article-title":"Outcome of donor-derived TAA-T cell therapy in patients with high-risk or relapsed acute leukemia post allogeneic BMT","volume":"6","author":"Kinoshita","year":"2022","journal-title":"Blood Adv"},{"issue":"4","key":"2025062410165153000_bib15","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1084\/jem.188.4.619","article-title":"Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes","volume":"188","author":"Krause","year":"1998","journal-title":"J Exp Med"},{"issue":"1","key":"2025062410165153000_bib16","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/nbt0102-70","article-title":"Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta \/CD28 receptor","volume":"20","author":"Maher","year":"2002","journal-title":"Nat Biotechnol"},{"issue":"95","key":"2025062410165153000_bib17","doi-asserted-by":"crossref","first-page":"95ra73","DOI":"10.1126\/scitranslmed.3002842","article-title":"T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia","volume":"3","author":"Kalos","year":"2011","journal-title":"Sci Transl Med"},{"issue":"8","key":"2025062410165153000_bib18","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N Engl J Med"},{"issue":"6","key":"2025062410165153000_bib19","doi-asserted-by":"crossref","first-page":"2114254","DOI":"10.1080\/21645515.2022.2114254","article-title":"Current updates on generations, approvals, and clinical trials of CAR T-cell therapy","volume":"18","author":"Asmamaw Dejenie","year":"2022","journal-title":"Hum Vaccines Immunother"},{"issue":"5","key":"2025062410165153000_bib20","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.3390\/cancers14051241","article-title":"Emerging CAR T cell strategies for the treatment of AML","volume":"14","author":"Vishwasrao","year":"2022","journal-title":"Cancers"},{"issue":"18","key":"2025062410165153000_bib21","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.3390\/cancers13184519","article-title":"Trial watch: adoptive TCR-engineered T-cell immunotherapy for acute myeloid leukemia","volume":"13","author":"Campillo-Davo","year":"2021","journal-title":"Cancers"},{"issue":"3","key":"2025062410165153000_bib22","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s40259-021-00477-8","article-title":"CAR-T cell therapy for acute myeloid leukemia: preclinical rationale, current clinical progress, and barriers to success","volume":"35","author":"Fiorenza","year":"2021","journal-title":"BioDrugs"},{"key":"2025062410165153000_bib23","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-024-01093-7","article-title":"From TCR fundamental research to innovative chimeric antigen receptor design","author":"Minguet","year":"21  2024","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"2025062410165153000_bib24","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/ni1058","article-title":"T cell killing does not require the formation of a stable mature immunological synapse","volume":"5","author":"Purbhoo","year":"2004","journal-title":"Nat Immunol"},{"issue":"6","key":"2025062410165153000_bib25","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S1074-7613(00)80483-5","article-title":"Evidence that a single peptide\u2013MHC complex on a target cell can elicit a cytolytic T cell response","volume":"4","author":"Sykulev","year":"1996","journal-title":"Immunity"},{"issue":"3","key":"2025062410165153000_bib26","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.tips.2015.11.004","article-title":"Adoptive T cell therapies: a comparison of T cell receptors and chimeric antigen receptors","volume":"37","author":"Harris","year":"2016","journal-title":"Trends Pharmacol Sci"},{"issue":"755","key":"2025062410165153000_bib27","doi-asserted-by":"crossref","first-page":"eadg7123","DOI":"10.1126\/scitranslmed.adg7123","article-title":"Preclinical studies show that Co-STARs combine the advantages of chimeric antigen and T cell receptors for the treatment of tumors with low antigen densities","volume":"16","author":"Mog","year":"2024","journal-title":"Sci Transl Med"},{"issue":"697","key":"2025062410165153000_bib28","doi-asserted-by":"crossref","first-page":"eabe2606","DOI":"10.1126\/scisignal.abe2606","article-title":"Comparative analysis of TCR and CAR signaling informs CAR designs with superior antigen sensitivity and in vivo function","volume":"14","author":"Salter","year":"2021","journal-title":"Sci Signal"},{"key":"2025062410165153000_bib29","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.molimm.2021.07.018","article-title":"Extensive functional comparisons between chimeric antigen receptors and T cell receptors highlight fundamental similarities","volume":"138","author":"Wang","year":"2021","journal-title":"Mol Immunol"},{"issue":"11","key":"2025062410165153000_bib30","doi-asserted-by":"crossref","first-page":"5733","DOI":"10.4049\/jimmunol.1301769","article-title":"Functional comparison of engineered T cells carrying a native TCR versus TCR-like antibody\u2013based chimeric antigen receptors indicates affinity\/avidity thresholds","volume":"193","author":"Oren","year":"2014","journal-title":"J Immunol"},{"issue":"11","key":"2025062410165153000_bib31","doi-asserted-by":"crossref","first-page":"114949","DOI":"10.1016\/j.celrep.2024.114949","article-title":"TCR-mimicking STAR conveys superior sensitivity over CAR in targeting tumors with low-density neoantigens","volume":"43","author":"Huang","year":"2024","journal-title":"Cell Rep"},{"issue":"6527","key":"2025062410165153000_bib32","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/375148a0","article-title":"Serial triggering of many T-cell receptors by a few peptide\u2013MHC complexes","volume":"375","author":"Valitutti","year":"1995","journal-title":"Nature"},{"issue":"3","key":"2025062410165153000_bib33","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.4049\/jimmunol.1700236","article-title":"Comparison of T cell activities mediated by human TCRs and CARs that use the same recognition domains","volume":"200","author":"Harris","year":"2018","journal-title":"J Immunol"},{"issue":"22","key":"2025062410165153000_bib34","doi-asserted-by":"crossref","first-page":"14255","DOI":"10.3390\/ijms232214255","article-title":"Learning from TCR signaling and immunological synapse assembly to build new chimeric antigen receptors (CARs)","volume":"23","author":"Cassioli","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"D1","key":"2025062410165153000_bib35","first-page":"D783","article-title":"Allele frequency net database (AFND) 2020 update: gold-standard data classification, open access genotype data and new query tools","volume":"48","author":"Gonzalez-Galarza","year":"2020","journal-title":"Nucleic Acids Res"},{"issue":"631","key":"2025062410165153000_bib36","doi-asserted-by":"crossref","first-page":"eabg8027","DOI":"10.1126\/scitranslmed.abg8027","article-title":"CRISPR-based gene disruption and integration of high-avidity, WT1-specific T cell receptors improve antitumor T cell function","volume":"14","author":"Ruggiero","year":"2022","journal-title":"Sci Transl Med"},{"issue":"6","key":"2025062410165153000_bib37","doi-asserted-by":"crossref","first-page":"e004409","DOI":"10.1136\/jitc-2021-004409","article-title":"WT1-specific TCRs directed against newly identified peptides install antitumor reactivity against acute myeloid leukemia and ovarian carcinoma","volume":"10","author":"van Amerongen","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"631","key":"2025062410165153000_bib38","doi-asserted-by":"crossref","first-page":"eabg8070","DOI":"10.1126\/scitranslmed.abg8070","article-title":"Targeting an alternate Wilms\u2019 tumor antigen 1 peptide bypasses immunoproteasome dependency","volume":"14","author":"Lahman","year":"2022","journal-title":"Sci Transl Med"},{"issue":"9","key":"2025062410165153000_bib39","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1182\/blood-2005-01-0146","article-title":"Elimination of human leukemia cells in NOD\/SCID mice by WT1-TCR gene\u2013transduced human T cells","volume":"106","author":"Xue","year":"2005","journal-title":"Blood"},{"issue":"1","key":"2025062410165153000_bib40","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1172\/JCI75876","article-title":"Survivin-specific T cell receptor targets tumor but not T cells","volume":"125","author":"Arber","year":"2015","journal-title":"J Clin Invest"},{"issue":"9","key":"2025062410165153000_bib41","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1158\/0008-5472.CAN-15-2318","article-title":"Feasibility of telomerase-specific adoptive T-cell therapy for B-cell chronic lymphocytic leukemia and solid malignancies","volume":"76","author":"Sandri","year":"2016","journal-title":"Cancer Res"},{"issue":"50","key":"2025062410165153000_bib42","doi-asserted-by":"crossref","first-page":"86987","DOI":"10.18632\/oncotarget.18115","article-title":"Effective control of acute myeloid leukaemia and acute lymphoblastic leukaemia progression by telomerase specific adoptive T-cell therapy","volume":"8","author":"Sandri","year":"2017","journal-title":"Oncotarget"},{"issue":"5","key":"2025062410165153000_bib43","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.3324\/haematol.2019.222612","article-title":"TARP is an immunotherapeutic target in acute myeloid leukemia expressed in the leukemic stem cell compartment","volume":"105","author":"Depreter","year":"2020","journal-title":"Haematologica"},{"issue":"17","key":"2025062410165153000_bib44","doi-asserted-by":"crossref","first-page":"5615","DOI":"10.1158\/1078-0432.CCR-11-1066","article-title":"PRAME-specific allo-HLA\u2013restricted T cells with potent antitumor reactivity useful for therapeutic T-cell receptor gene transfer","volume":"17","author":"Amir","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"42","key":"2025062410165153000_bib45","doi-asserted-by":"crossref","first-page":"4696","DOI":"10.1038\/s41388-022-02455-y","article-title":"Decitabine enhances targeting of AML cells by NY-ESO-1-specific TCR-T cells and promotes the maintenance of effector function and the memory phenotype","volume":"41","author":"Kang","year":"2022","journal-title":"Oncogene"},{"issue":"2","key":"2025062410165153000_bib46","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1084\/jem.187.2.265","article-title":"Simultaneous humoral and cellular immune response against cancer\u2013testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2\u2013binding peptide epitopes","volume":"187","author":"J\u00e4ger","year":"1998","journal-title":"J Exp Med"},{"issue":"2","key":"2025062410165153000_bib47","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1182\/blood-2011-06-360354","article-title":"Aurora kinase A-specific T-cell receptor gene transfer redirects T lymphocytes to display effective antileukemia reactivity","volume":"119","author":"Nagai","year":"2012","journal-title":"Blood"},{"issue":"15","key":"2025062410165153000_bib48","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1182\/blood-2011-06-357939","article-title":"TCR-transgenic lymphocytes specific for HMMR\/Rhamm limit tumor outgrowth in vivo","volume":"119","author":"Spranger","year":"2012","journal-title":"Blood"},{"issue":"3","key":"2025062410165153000_bib49","doi-asserted-by":"crossref","first-page":"477","DOI":"10.3324\/haematol.2010.025916","article-title":"Optimization of the HA-1-specific T-cell receptor for gene therapy of hematologic malignancies","volume":"96","author":"van Loenen","year":"2011","journal-title":"Haematologica"},{"issue":"1","key":"2025062410165153000_bib50","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1182\/blood-2017-07-791608","article-title":"Development of T-cell immunotherapy for hematopoietic stem cell transplantation recipients at risk of leukemia relapse","volume":"131","author":"Dossa","year":"2018","journal-title":"Blood"},{"issue":"5","key":"2025062410165153000_bib51","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.3390\/cancers15051592","article-title":"Transgenic HA-1-specific CD8+ T-lymphocytes selectively target leukemic cells","volume":"15","author":"Pilunov","year":"2023","journal-title":"Cancers"},{"issue":"2","key":"2025062410165153000_bib52","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1172\/JCI97482","article-title":"Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia","volume":"129","author":"van der Lee","year":"2019","journal-title":"J Clin Invest"},{"issue":"21","key":"2025062410165153000_bib53","doi-asserted-by":"crossref","first-page":"5390","DOI":"10.3390\/cancers13215390","article-title":"An HLA-A\u221711:01-binding neoantigen from mutated NPM1 as target for TCR gene therapy in AML","volume":"13","author":"van der Lee","year":"2021","journal-title":"Cancers"},{"issue":"10","key":"2025062410165153000_bib54","doi-asserted-by":"crossref","first-page":"5127","DOI":"10.1172\/JCI137723","article-title":"CBFB-MYH11 fusion neoantigen enables T cell recognition and killing of acute myeloid leukemia","volume":"130","author":"Biernacki","year":"2020","journal-title":"J Clin Invest"},{"issue":"12","key":"2025062410165153000_bib55","doi-asserted-by":"crossref","first-page":"e007490","DOI":"10.1136\/jitc-2023-007490","article-title":"Discovery of U2AF1 neoantigens in myeloid neoplasms","volume":"11","author":"Biernacki","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"10","key":"2025062410165153000_bib56","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1038\/s43018-023-00642-8","article-title":"A T cell receptor targeting a recurrent driver mutation in FLT3 mediates elimination of primary human acute myeloid leukemia in vivo","volume":"4","author":"Giannakopoulou","year":"2023","journal-title":"Nat Cancer"},{"issue":"17","key":"2025062410165153000_bib57","doi-asserted-by":"crossref","first-page":"5323","DOI":"10.1158\/1078-0432.CCR-09-0737","article-title":"The prioritization of cancer antigens: a National Cancer Institute pilot project for the acceleration of translational research","volume":"15","author":"Cheever","year":"2009","journal-title":"Clin Cancer Res"},{"key":"2025062410165153000_bib58","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3389\/fped.2020.00284","article-title":"Minor histocompatibility antigen-specific T cells","volume":"8","author":"Summers","year":"2020","journal-title":"Front Pediatr"},{"issue":"10","key":"2025062410165153000_bib59","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1038\/leu.2017.86","article-title":"The mutational oncoprint of recurrent cytogenetic abnormalities in adult patients with de novo acute myeloid leukemia","volume":"31","author":"Eisfeld","year":"2017","journal-title":"Leukemia"},{"issue":"4","key":"2025062410165153000_bib60","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.immuni.2021.03.001","article-title":"Atypical acute myeloid leukemia-specific transcripts generate shared and immunogenic MHC class-I-associated epitopes","volume":"54","author":"Ehx","year":"2021","journal-title":"Immunity"},{"issue":"12","key":"2025062410165153000_bib61","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1038\/s41573-023-00809-z","article-title":"T cell receptor therapeutics: immunologic targeting of the intracellular cancer proteome","volume":"22","author":"Klebanoff","year":"2023","journal-title":"Nat Rev Drug Discov"},{"issue":"11","key":"2025062410165153000_bib62","doi-asserted-by":"crossref","first-page":"3869","DOI":"10.1172\/JCI43437","article-title":"MHC-restricted fratricide of human lymphocytes expressing survivin-specific transgenic T cell receptors","volume":"120","author":"Leisegang","year":"2010","journal-title":"J Clin Invest"},{"issue":"5","key":"2025062410165153000_bib63","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.4049\/jimmunol.1100852","article-title":"Allogeneic HLA-A\u221702\u2013restricted WT1-specific T cells from mismatched donors are highly reactive but show off-target promiscuity","volume":"187","author":"Falkenburg","year":"2011","journal-title":"J Immunol"},{"issue":"9","key":"2025062410165153000_bib64","first-page":"3360","article-title":"NetMHCpan 4.0: improved peptide-MHC class I interaction predictions integrating eluted ligand and peptide binding affinity data","volume":"199","author":"Jurtz","year":"2017","journal-title":"J Immunol 1950"},{"issue":"11","key":"2025062410165153000_bib65","doi-asserted-by":"crossref","first-page":"3873","DOI":"10.1182\/blood.V104.11.3873.3873","article-title":"Sensitization of human T cells with overlapping pentadecapeptides spanning the Wt1 protein induces expansion of leukemocidal T cells specific for both previously identified and novel WT1 epitopes","volume":"104","author":"Doubrovina","year":"2004","journal-title":"Blood"},{"issue":"8","key":"2025062410165153000_bib66","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.jcyt.2021.03.001","article-title":"Identification of novel HLA-restricted PRAME peptides to facilitate off-the-shelf tumor- associated antigen-specific T-cell therapies","volume":"23","author":"Stanojevic","year":"2021","journal-title":"Cytotherapy"},{"issue":"10","key":"2025062410165153000_bib67","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1038\/nbt.3662","article-title":"Large-scale detection of antigen-specific T cells using peptide-MHC-I multimers labeled with DNA barcodes","volume":"34","author":"Bentzen","year":"2016","journal-title":"Nat Biotechnol"},{"issue":"10","key":"2025062410165153000_bib68","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1016\/j.immuni.2022.09.004","article-title":"High-throughput T cell receptor engineering by functional screening identifies candidates with enhanced potency and specificity","volume":"55","author":"Vazquez-Lombardi","year":"2022","journal-title":"Immunity"},{"issue":"2","key":"2025062410165153000_bib69","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1021\/acs.analchem.1c03678","article-title":"High-throughput functional screening of antigen-specific T cells based on droplet microfluidics at a single-cell level","volume":"94","author":"Wang","year":"2022","journal-title":"Anal Chem"},{"issue":"6","key":"2025062410165153000_bib70","doi-asserted-by":"crossref","first-page":"e68201","DOI":"10.1371\/journal.pone.0068201","article-title":"Comparison of lentiviral and sleeping beauty mediated \u03b1\u03b2 T cell receptor gene transfer","volume":"8","author":"Field","year":"2013","journal-title":"PLoS One"},{"issue":"6","key":"2025062410165153000_bib71","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/mt.2016.51","article-title":"Stable, nonviral expression of mutated tumor neoantigen-specific T-cell receptors using the sleeping beauty transposon\/transposase system","volume":"24","author":"Deniger","year":"2016","journal-title":"Mol Ther"},{"issue":"17","key":"2025062410165153000_bib72","doi-asserted-by":"crossref","first-page":"8878","DOI":"10.1158\/0008-5472.CAN-06-1450","article-title":"Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR\/CD3 stability","volume":"66","author":"Cohen","year":"2006","journal-title":"Cancer Res"},{"issue":"22","key":"2025062410165153000_bib73","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1182\/blood.V114.22.3583.3583","article-title":"Transfer of human T-cell receptors (TCR) containing murine chimeric constant beta-gamma-chain sequences reduces the risk of mixed heterodimers and shows enhanced in vitro-accumulation of TCR-tranduced effector cells","volume":"114","author":"Krackhardt","year":"2009","journal-title":"Blood"},{"issue":"6","key":"2025062410165153000_bib74","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1182\/blood-2006-05-023069","article-title":"Facilitating matched pairing and expression of TCR chains introduced into human T cells","volume":"109","author":"Kuball","year":"2007","journal-title":"Blood"},{"issue":"8","key":"2025062410165153000_bib75","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1158\/0008-5472.CAN-06-3986","article-title":"Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond","volume":"67","author":"Cohen","year":"2007","journal-title":"Cancer Res"},{"issue":"3","key":"2025062410165153000_bib76","doi-asserted-by":"crossref","first-page":"101469","DOI":"10.1016\/j.xcrm.2024.101469","article-title":"DNAJB1-PRKACA fusion neoantigens elicit rare endogenous T cell responses that potentiate cell therapy for fibrolamellar carcinoma","volume":"5","author":"Kirk","year":"2024","journal-title":"Cell Rep Med"},{"issue":"9","key":"2025062410165153000_bib77","first-page":"6116","article-title":"Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions","volume":"180","author":"Robbins","year":"2008","journal-title":"J Immunol 1950"},{"issue":"3","key":"2025062410165153000_bib78","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nbt1070","article-title":"Directed evolution of human T-cell receptors with picomolar affinities by phage display","volume":"23","author":"Li","year":"2005","journal-title":"Nat Biotechnol"},{"issue":"9","key":"2025062410165153000_bib79","first-page":"5845","article-title":"High-affinity TCRs generated by phage display provide CD4+ T cells with the ability to recognize and kill tumor cell lines","volume":"179","author":"Zhao","year":"2007","journal-title":"J Immunol 1950"},{"issue":"10","key":"2025062410165153000_bib80","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1002\/ijc.32612","article-title":"Optimizing T-cell receptor avidity with somatic hypermutation","volume":"145","author":"Bassan","year":"2019","journal-title":"Int J Cancer"},{"issue":"3","key":"2025062410165153000_bib81","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/mt.2010.272","article-title":"T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis","volume":"19","author":"Parkhurst","year":"2011","journal-title":"Mol Ther"},{"issue":"2","key":"2025062410165153000_bib82","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/CJI.0b013e3182829903","article-title":"Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy","volume":"36","author":"Morgan","year":"2013","journal-title":"J Immunother"},{"issue":"6","key":"2025062410165153000_bib83","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood-2013-03-490565","article-title":"Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma","volume":"122","author":"Linette","year":"2013","journal-title":"Blood"},{"issue":"1-2","key":"2025062410165153000_bib84","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jim.2013.02.018","article-title":"Engineering improved T cell receptors using an alanine-scan guided T cell display selection system","volume":"392","author":"Malecek","year":"2013","journal-title":"J Immunol Methods"},{"issue":"2","key":"2025062410165153000_bib85","doi-asserted-by":"crossref","first-page":"e1532759","DOI":"10.1080\/2162402X.2018.1532759","article-title":"Affinity-enhanced T-cell receptors for adoptive T-cell therapy targeting MAGE-A10: strategy for selection of an optimal candidate","volume":"8","author":"Border","year":"2019","journal-title":"OncoImmunology"},{"issue":"12","key":"2025062410165153000_bib86","doi-asserted-by":"crossref","first-page":"btad743","DOI":"10.1093\/bioinformatics\/btad743","article-title":"EPIC-TRACE: predicting TCR binding to unseen epitopes using attention and contextualized embeddings","volume":"39","author":"Korpela","year":"2023","journal-title":"Bioinformatics"},{"key":"2025062410165153000_bib87","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.3389\/fimmu.2020.01803","article-title":"Prediction of specific TCR-peptide binding from large dictionaries of TCR-peptide pairs","volume":"11","author":"Springer","year":"2020","journal-title":"Front Immunol"},{"key":"2025062410165153000_bib88","doi-asserted-by":"crossref","first-page":"664514","DOI":"10.3389\/fimmu.2021.664514","article-title":"Contribution of T cell receptor alpha and beta CDR3, MHC typing, V and J genes to peptide binding prediction","volume":"12","author":"Springer","year":"2021","journal-title":"Front Immunol"},{"key":"2025062410165153000_bib89","doi-asserted-by":"crossref","first-page":"585385","DOI":"10.3389\/fimmu.2020.585385","article-title":"Empirical and rational design of T cell receptor-based immunotherapies","volume":"11","author":"Jones","year":"2020","journal-title":"Front Immunol"},{"issue":"24","key":"2025062410165153000_bib90","doi-asserted-by":"crossref","first-page":"10024","DOI":"10.1073\/pnas.86.24.10024","article-title":"Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity","volume":"86","author":"Gross","year":"1989","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"2025062410165153000_bib91","doi-asserted-by":"crossref","first-page":"e65212","DOI":"10.1371\/journal.pone.0065212","article-title":"Extracellular domains of CD8\u03b1 and CD8\u00df subunits are sufficient for HLA class I restricted helper functions of TCR-engineered CD4+ T cells","volume":"8","author":"van Loenen","year":"2013","journal-title":"PLoS One"},{"issue":"4","key":"2025062410165153000_bib92","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/CJI.0000000000000456","article-title":"Enhancing efficacy of TCR-engineered CD4+ T cells via coexpression of CD8\u03b1","volume":"46","author":"Anderson","year":"2023","journal-title":"J Immunother"},{"issue":"6","key":"2025062410165153000_bib93","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1002\/eji.200636900","article-title":"CD8alpha\/alpha homodimers fail to function as co-receptor for a CD8-dependent TCR","volume":"37","author":"McNicol","year":"2007","journal-title":"Eur J Immunol"},{"issue":"1","key":"2025062410165153000_bib94","doi-asserted-by":"crossref","first-page":"e22590","DOI":"10.4161\/onci.22590","article-title":"Human MHC Class I-restricted high avidity CD4+ T cells generated by co-transfer of TCR and CD8 mediate efficient tumor rejection in vivo","volume":"2","author":"Xue","year":"2013","journal-title":"OncoImmunology"},{"issue":"27","key":"2025062410165153000_bib95","doi-asserted-by":"crossref","first-page":"eaaz7809","DOI":"10.1126\/sciadv.aaz7809","article-title":"Single-cell transcriptomics identifies multiple pathways underlying antitumor function of TCR- and CD8\u03b1\u03b2-engineered human CD4+ T cells","volume":"6","author":"Rath","year":"2020","journal-title":"Sci Adv"},{"issue":"11","key":"2025062410165153000_bib96","doi-asserted-by":"crossref","first-page":"5988","DOI":"10.4049\/jimmunol.1000189","article-title":"Both CD4 and CD8 T cells mediate equally effective in vivo tumor treatment when engineered with a highly avid TCR targeting tyrosinase","volume":"184","author":"Frankel","year":"2010","journal-title":"J Immunol"},{"issue":"13","key":"2025062410165153000_bib97","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1182\/blood-2011-04-346338","article-title":"CD3 limits the efficacy of TCR gene therapy in vivo","volume":"118","author":"Ahmadi","year":"2011","journal-title":"Blood"},{"issue":"12","key":"2025062410165153000_bib98","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1002\/ijc.28320","article-title":"Enhanced antitumor activity mediated by human 4-1BB-engineered T cells","volume":"133","author":"Daniel-Meshulam","year":"2013","journal-title":"Int J Cancer"},{"issue":"1","key":"2025062410165153000_bib99","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2174\/1875037001104010011","article-title":"T cell receptor fused to CD3\u03b6: transmembrane domain of CD3\u03b6 prevents TCR mis-pairing, whereas complete CD3\u03b6 directs functional TCR expression","volume":"4","author":"Debets","year":"2011","journal-title":"Open Gene Ther J"},{"issue":"11","key":"2025062410165153000_bib100","doi-asserted-by":"crossref","first-page":"7736","DOI":"10.4049\/jimmunol.180.11.7736","article-title":"Human TCR that incorporate CD3zeta induce highly preferred pairing between TCR\u03b1 and \u03b2 chains following gene transfer1","volume":"180","author":"Sebesty\u00e9n","year":"2008","journal-title":"J Immunol"},{"issue":"5","key":"2025062410165153000_bib101","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1002\/eji.200940233","article-title":"T-cell synapse formation depends on antigen recognition but not CD3 interaction: studies with TCR:\u03b6, a candidate transgene for TCR gene therapy","volume":"41","author":"Roszik","year":"2011","journal-title":"Eur J Immunol"},{"issue":"16","key":"2025062410165153000_bib102","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1038\/sj.gt.3301253","article-title":"Grafting primary human T lymphocytes with cancer-specific chimeric single chain and two chain TCR","volume":"7","author":"Willemsen","year":"2000","journal-title":"Gene Ther"},{"issue":"10","key":"2025062410165153000_bib103","doi-asserted-by":"crossref","first-page":"5315","DOI":"10.4049\/jimmunol.1302074","article-title":"TCRs genetically linked to CD28 and CD3\u03b5 do not mispair with endogenous TCR chains and mediate enhanced T cell persistence and anti-melanoma activity","volume":"193","author":"Govers","year":"2014","journal-title":"J Immunol"},{"issue":"6","key":"2025062410165153000_bib104","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1158\/2326-6066.CIR-17-0538","article-title":"Introduction of genetically modified CD3\u03b6 improves proliferation and persistence of antigen-specific CTLs","volume":"6","author":"Miyao","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"2025062410165153000_bib105","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.omto.2020.08.014","article-title":"Artificial T cell adaptor molecule-transduced TCR-T cells demonstrated improved proliferation only when transduced in a higher intensity","volume":"18","author":"Sakai","year":"2020","journal-title":"Mol Ther Oncolytics"},{"issue":"17","key":"2025062410165153000_bib106","doi-asserted-by":"crossref","first-page":"6725","DOI":"10.1158\/0008-5472.CAN-10-0735","article-title":"Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts","volume":"70","author":"Kerkar","year":"2010","journal-title":"Cancer Res"},{"issue":"1","key":"2025062410165153000_bib107","doi-asserted-by":"crossref","first-page":"e1378842","DOI":"10.1080\/2162402X.2017.1378842","article-title":"Intra-tumoral production of IL18, but not IL12, by TCR-engineered T cells is non-toxic and counteracts immune evasion of solid tumors","volume":"7","author":"Kunert","year":"2017","journal-title":"OncoImmunology"},{"issue":"10","key":"2025062410165153000_bib108","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1158\/1078-0432.CCR-14-2085","article-title":"Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma","volume":"21","author":"Zhang","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2025062410165153000_bib109","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/mt.2010.313","article-title":"Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment","volume":"19","author":"Zhang","year":"2011","journal-title":"Mol Ther"},{"issue":"3","key":"2025062410165153000_bib110","doi-asserted-by":"crossref","first-page":"1542917","DOI":"10.1080\/2162402X.2018.1542917","article-title":"Safety and efficacy of Tet-regulated IL-12 expression in cancer-specific T cells","volume":"8","author":"Alsaieedi","year":"2019","journal-title":"OncoImmunology"},{"key":"2025062410165153000_bib111","doi-asserted-by":"crossref","first-page":"1062365","DOI":"10.3389\/fimmu.2023.1062365","article-title":"Reprogramming of IL-12 secretion in the PDCD1 locus improves the anti-tumor activity of NY-ESO-1 TCR-T cells","volume":"14","author":"Kim","year":"2023","journal-title":"Front Immunol"},{"issue":"1","key":"2025062410165153000_bib112","doi-asserted-by":"crossref","first-page":"e000210","DOI":"10.1136\/jitc-2019-000210","article-title":"Enhanced efficacy and limited systemic cytokine exposure with membrane-anchored interleukin-12 T-cell therapy in murine tumor models","volume":"8","author":"Zhang","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"8","key":"2025062410165153000_bib113","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.3390\/cancers14081998","article-title":"T-cells expressing a highly potent PRAME-specific T-cell receptor in combination with a chimeric PD1-41BB co-stimulatory receptor show a favorable preclinical safety profile and strong anti-tumor reactivity","volume":"14","author":"Sailer","year":"2022","journal-title":"Cancers"},{"key":"2025062410165153000_bib114","doi-asserted-by":"crossref","first-page":"1315283","DOI":"10.3389\/fimmu.2024.1315283","article-title":"TIM-3, LAG-3, or 2B4 gene disruptions increase the anti-tumor response of engineered T cells","volume":"15","author":"Cianciotti","year":"2024","journal-title":"Front Immunol"},{"issue":"4","key":"2025062410165153000_bib115","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1158\/2326-6066.CIR-21-0307","article-title":"A costimulatory CAR improves TCR-based cancer immunotherapy","volume":"10","author":"Omer","year":"2022","journal-title":"Cancer Immunol Res"},{"issue":"2","key":"2025062410165153000_bib116","doi-asserted-by":"crossref","first-page":"200797","DOI":"10.1016\/j.omton.2024.200797","article-title":"CAR\u2019TCR-T cells co-expressing CD33-CAR and dNPM1-TCR as superior dual-targeting approach for AML treatment","volume":"32","author":"Teppert","year":"2024","journal-title":"Mol Ther Oncol"},{"issue":"5","key":"2025062410165153000_bib117","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/nm.2700","article-title":"Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer","volume":"18","author":"Provasi","year":"2012","journal-title":"Nat Med"},{"issue":"11","key":"2025062410165153000_bib118","doi-asserted-by":"crossref","first-page":"4172","DOI":"10.1111\/cas.15954","article-title":"T cell receptor gene-modified allogeneic T cells with siRNA for endogenous T cell receptor induce efficient tumor regression without graft-versus-host disease","volume":"114","author":"Okada","year":"2023","journal-title":"Cancer Sci"},{"key":"2025062410165153000_bib119","doi-asserted-by":"crossref","first-page":"109055","DOI":"10.1016\/j.intimp.2022.109055","article-title":"CRISPR\/Cas9-medaited knockout of endogenous T-cell receptor in Jurkat cells and generation of NY-ESO-1-specific T cells: an in vitro study","volume":"110","author":"Safarzadeh Kozani","year":"2022","journal-title":"Int Immunopharmacol"},{"issue":"9","key":"2025062410165153000_bib120","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1158\/2326-6066.CIR-21-0095","article-title":"CRASH-IT switch enables reversible and dose-dependent control of TCR and CAR T-cell function","volume":"9","author":"Sahillioglu","year":"2021","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"2025062410165153000_bib121","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1182\/blood-2010-12-325993","article-title":"Redirecting \u03b1\u03b2 T cells against cancer cells by transfer of a broadly tumor-reactive \u03b3\u03b4T-cell receptor","volume":"118","author":"Marcu-Malina","year":"2011","journal-title":"Blood"},{"issue":"1","key":"2025062410165153000_bib122","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s40425-019-0558-4","article-title":"Evaluating in vivo efficacy \u2013 toxicity profile of TEG001 in humanized mice xenografts against primary human AML disease and healthy hematopoietic cells","volume":"7","author":"Johanna","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"suppl 1","key":"2025062410165153000_bib123","doi-asserted-by":"crossref","first-page":"12737","DOI":"10.1182\/blood-2022-158191","article-title":"First in human clinical responses and persistence data on TEG001: a next generation of engineered \u0391\u03b2 T cells targeting AML and MM with a high affinity \u03b39\u03b42TCR","volume":"140","author":"de Witte","year":"2022","journal-title":"Blood"},{"issue":"7","key":"2025062410165153000_bib124","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1084\/jem.20140410","article-title":"A novel self-lipid antigen targets human T cells against CD1c+ leukemias","volume":"211","author":"Lepore","year":"2014","journal-title":"J Exp Med"},{"issue":"1","key":"2025062410165153000_bib125","doi-asserted-by":"crossref","first-page":"4844","DOI":"10.1038\/s41467-021-25223-0","article-title":"Human T cells engineered with a leukemia lipid-specific TCR enables donor-unrestricted recognition of CD1c-expressing leukemia","volume":"12","author":"Consonni","year":"2021","journal-title":"Nat Commun"},{"issue":"1","key":"2025062410165153000_bib126","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1038\/s41467-019-10097-0","article-title":"Synthetic TRuC receptors engaging the complete T cell receptor for potent anti-tumor response","volume":"10","author":"Baeuerle","year":"2019","journal-title":"Nat Commun"},{"issue":"1","key":"2025062410165153000_bib127","doi-asserted-by":"crossref","first-page":"2182058","DOI":"10.1080\/2162402X.2023.2182058","article-title":"Mesothelin-targeting T cells bearing a novel T cell receptor fusion construct (TRuC) exhibit potent antitumor efficacy against solid tumors","volume":"12","author":"Ding","year":"2023","journal-title":"OncoImmunology"},{"issue":"1","key":"2025062410165153000_bib128","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1038\/s41467-018-05395-y","article-title":"The chimeric TAC receptor co-opts the T cell receptor yielding robust anti-tumor activity without toxicity","volume":"9","author":"Helsen","year":"2018","journal-title":"Nat Commun"},{"issue":"586","key":"2025062410165153000_bib129","doi-asserted-by":"crossref","first-page":"eabb5191","DOI":"10.1126\/scitranslmed.abb5191","article-title":"Chimeric STAR receptors using TCR machinery mediate robust responses against solid tumors","volume":"13","author":"Liu","year":"2021","journal-title":"Sci Transl Med"},{"issue":"2","key":"2025062410165153000_bib130","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41591-021-01621-1","article-title":"HLA-independent T cell receptors for targeting tumors with low antigen density","volume":"28","author":"Mansilla-Soto","year":"2022","journal-title":"Nat Med"},{"issue":"suppl 7","key":"2025062410165153000_bib131","article-title":"Development of LILRB4 biparatopic synthetic T-cell receptor and antigen receptor (STAR)-T cells for the treatment of acute myeloid leukemia (AML) [abstract]","volume":"83","author":"Rui","year":"2023","journal-title":"Cancer Res"},{"issue":"1","key":"2025062410165153000_bib132","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/s41421-018-0066-6","article-title":"A novel antibody-TCR (AbTCR) platform combines Fab-based antigen recognition with gamma\/delta-TCR signaling to facilitate T-cell cytotoxicity with low cytokine release","volume":"4","author":"Xu","year":"2018","journal-title":"Cell Discov"},{"issue":"9","key":"2025062410165153000_bib133","doi-asserted-by":"crossref","first-page":"e25581","DOI":"10.4161\/onci.25581","article-title":"Continuous 4\u20131BB co-stimulatory signals for the optimal expansion of tumor-infiltrating lymphocytes for adoptive T-cell therapy","volume":"2","author":"Chacon","year":"2013","journal-title":"OncoImmunology"},{"issue":"22","key":"2025062410165153000_bib134","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1182\/blood-2017-04-777052","article-title":"A CD200R-CD28 fusion protein appropriates an inhibitory signal to enhance T-cell function and therapy of murine leukemia","volume":"130","author":"Oda","year":"2017","journal-title":"Blood"},{"issue":"12","key":"2025062410165153000_bib135","doi-asserted-by":"crossref","first-page":"e20191166","DOI":"10.1084\/jem.20191166","article-title":"A Fas-4-1BB fusion protein converts a death to a pro-survival signal and enhances T cell therapy","volume":"217","author":"Oda","year":"2020","journal-title":"J Exp Med"},{"issue":"2","key":"2025062410165153000_bib136","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1158\/1078-0432.CCR-20-1457","article-title":"CD19-specific CAR T cells that express a PD-1\/CD28 chimeric switch-receptor are effective in patients with PD-L1\u2013positive B-cell lymphoma","volume":"27","author":"Liu","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"7714","key":"2025062410165153000_bib137","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/s41586-018-0326-5","article-title":"Reprogramming human T cell function and specificity with non-viral genome targeting","volume":"559","author":"Roth","year":"2018","journal-title":"Nature"},{"issue":"12","key":"2025062410165153000_bib138","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1038\/s41551-019-0409-0","article-title":"Orthotopic replacement of T-cell receptor \u03b1- and \u03b2-chains with preservation of near-physiological T-cell function","volume":"3","author":"Schober","year":"2019","journal-title":"Nat Biomed Eng"},{"issue":"11","key":"2025062410165153000_bib139","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1182\/blood-2004-11-4564","article-title":"An inducible caspase 9 safety switch for T-cell therapy","volume":"105","author":"Straathof","year":"2005","journal-title":"Blood"},{"issue":"5","key":"2025062410165153000_bib140","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1182\/blood-2011-02-337360","article-title":"A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells","volume":"118","author":"Wang","year":"2011","journal-title":"Blood"},{"issue":"8","key":"2025062410165153000_bib141","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1182\/blood-2014-01-545020","article-title":"A highly compact epitope-based marker\/suicide gene for easier and safer T-cell therapy","volume":"124","author":"Philip","year":"2014","journal-title":"Blood"},{"issue":"2","key":"2025062410165153000_bib142","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1073\/pnas.0710198105","article-title":"A safeguard eliminates T cell receptor gene-modified autoreactive T cells after adoptive transfer","volume":"105","author":"Kieback","year":"2008","journal-title":"Proc Natl Acad Sci"},{"key":"2025062410165153000_bib143","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2014.00679","article-title":"Phosphoantigen presentation to TCR \u03b3\u03b4 Cells, a conundrum getting less gray zones","volume":"5","author":"De Libero","year":"2015","journal-title":"Front Immunol"},{"issue":"1","key":"2025062410165153000_bib144","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1146\/annurev.immunol.17.1.297","article-title":"The CD1 system: antigen-presenting molecules for T cell recognition of lipids and glycolipids","volume":"17","author":"Porcelli","year":"1999","journal-title":"Annu Rev Immunol"},{"issue":"7988","key":"2025062410165153000_bib145","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/s41586-023-06706-0","article-title":"Targeting of intracellular oncoproteins with peptide-centric CARs","volume":"623","author":"Yarmarkovich","year":"2023","journal-title":"Nature"},{"issue":"8","key":"2025062410165153000_bib146","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1182\/blood.2021012882","article-title":"A TCR mimic CAR T cell specific for NDC80 is broadly reactive with solid tumors and hematologic malignancies","volume":"140","author":"Klatt","year":"2022","journal-title":"Blood"},{"issue":"18","key":"2025062410165153000_bib147","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1182\/blood-2017-06-791202","article-title":"Safety and persistence of WT1-specific T-cell receptor gene\u2212transduced lymphocytes in patients with AML and MDS","volume":"130","author":"Tawara","year":"2017","journal-title":"Blood"},{"issue":"7","key":"2025062410165153000_bib148","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1038\/s41591-019-0472-9","article-title":"T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant","volume":"25","author":"Chapuis","year":"2019","journal-title":"Nat Med"},{"issue":"suppl_1","key":"2025062410165153000_bib149","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1182\/blood-2019-128044","article-title":"A phase I study evaluating the safety and persistence of allorestricted WT1-TCR gene modified autologous T cells in patients with high-risk myeloid malignancies unsuitable for allogeneic stem cell transplantation","volume":"134","author":"Morris","year":"2019","journal-title":"Blood"},{"issue":"10","key":"2025062410165153000_bib150","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1182\/blood.2024024105","article-title":"HA-1-targeted T cell receptor (TCR) T cell therapy for recurrent leukemia after hematopoietic stem cell transplantation","volume":"144","author":"Krakow","year":"2024","journal-title":"Blood"},{"key":"2025062410165153000_bib151","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.3389\/fimmu.2020.01804","article-title":"HA-1H T-cell receptor gene transfer to redirect virus-specific T cells for treatment of hematological malignancies after allogeneic stem cell transplantation: a phase 1 clinical study","volume":"11","author":"van Balen","year":"2020","journal-title":"Front Immunol"},{"issue":"2","key":"2025062410165153000_bib152","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jtct.2023.12.020","article-title":"TSC-100 and TSC-101, TCR-T cell therapies that target residual recipient cells after reduced intensity conditioning transplantation, induce complete donor chimerism with favorable prognosis: early results of a phase 1 trial","volume":"30","author":"Al Malki","year":"2024","journal-title":"Transplant Cell"},{"issue":"suppl 1","key":"2025062410165153000_bib153","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1182\/blood-2023-187355","article-title":"Initial results of a phase 1 trial of TSC-100 and TSC-101, engineered T cell therapies that target minor histocompatibility antigens to prevent relapse after allogeneic hematopoietic cell transplantation","volume":"142","author":"Al Malki","year":"2023","journal-title":"Blood"},{"key":"2025062410165153000_bib154","unstructured":"EU Clinical Trials Register\n          . Clinical trial results: WT1 TCR gene therapy for leukaemia: a phase I\/II safety and toxicity study. EudraCT Number 2006-004950-25. Accessed 7 March 2024. https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2006-004950-25\/results."},{"issue":"suppl 1","key":"2025062410165153000_bib155","doi-asserted-by":"crossref","first-page":"7468","DOI":"10.1182\/blood-2022-167707","article-title":"Trial in progress: a phase 1 umbrella study of TCR-engineered T cells that target HA-1 (TSC-100) and HA-2 (TSC-101) to treat residual leukemia after hematopoietic cell transplantation","volume":"140","author":"Reshef","year":"2022","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/12\/3069\/2380111\/blooda_adv-2024-014105-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/12\/3069\/2380111\/blooda_adv-2024-014105-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T14:44:55Z","timestamp":1750776295000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/12\/3069\/535106\/Current-developments-in-T-cell-receptor-therapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,16]]},"references-count":155,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,6,24]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024014105","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6,24]]},"published":{"date-parts":[[2025,6,16]]}}}